Skip to search formSkip to main contentSkip to account menu

XL820

Known as: XL820-001 
An orally bioavailable, small molecule receptor tyrosine kinase inhibitor with potential antineoplastic activity. XL820 binds to and inhibits the… 
National Institutes of Health

Related topics

Related topics

1 relation
Receptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
212 POSTER A phase II study of the KIT inhibitor XL820 in patients with advanced gastrointestinal stromal tumors (GIST) resistant to or intolerant of imatinib and/or sunitinib
2007
2007
XL820 inhibits mutated forms of KIT associated with drug resistance.
B237 Background: Ligand-independent activation of KIT is a critical factor in gastrointestinal stromal tumor (GIST) pathogenesis… 
2007
2007
A phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of XL820 administered orally daily (QD) or twice daily (BID) to patients (pts) with solid malignancies
B69 Background: XL820 is a small molecule inhibitor of several receptor tyrosine kinases (RTKs) with growth-promoting and… 
2006
2006
Pipeline cherrypicking deal yields lucrative return
Exelixis is reaping the benefits of a licensing and development deal with GlaxoSmithKline that gives the pharma partner an option… 
2006
2006
97 POSTER A phase I dose-escalation study of the safety and pharmacokinetics of a novel spectrum selective kinase inhibitor, XL820, administered orally to patients with solid tumors
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)